Study of the Disease Process of Lymphangioleiomyomatosis

Key facts

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Principal Investigator

Joel Moss, M.D., MD

National Heart, Lung, and Blood Institute (NHLBI)

Intervention

Toshibia Aquilion One CT(device)

Enrollment

2000 enrolled

Eligibility

16-100 years · All sexes

Timeline

1995

Study locations (1)

• National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Tuberous sclerosis complex

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONNANCT06879665
  TANDem-2: Closing the Gap to Interventions for TAND
  Vrije Universiteit Brussel
• RECRUITINGPHASE3NCT07403266
  Treatment With Full-spectrum Cannabis Extract of Refractory Epilepsy Associated With Tuberous Sclerosis Complex (TSC)
  Oils4Cure
• RECRUITINGNANCT06160310
  Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)
  David M. Ritter
• RECRUITINGPHASE2NCT05104983
  Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
  Darcy Krueger
• RECRUITINGNANCT06764602
  Observational, Retrospective, Multicenter, Nonprofit Study on the Prevalence of Renal Involvement in Pediatric Patients With Tuberous Sclerosis
  IRCCS Azienda Ospedaliero-Universitaria di Bologna
• ACTIVE NOT RECRUITINGNANCT04198181
  The Effectiveness and Safety of Resective Epilepsy Surgery for TRE
  Beijing Children's Hospital
• ACTIVE NOT RECRUITINGPHASE3NCT02962414
  Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment
  Novartis Pharmaceuticals

See all trials for Tuberous sclerosis complex →